KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).

Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, Linda Koster, Marleen van Os, Uwe Platzbecker, Kai Hübel, Christof Scheid, Lutz Peter Müller, Matthias Stelljes, Elena Morozova, Jakob Passweg, Francesco Onida, Peter Dreger, Riccardo Saccardi, Marco Ladetto, Urpu Salmenniemi, Wolfgang Bethge, Xavier Poiré, Guido Kobbe, Donal P McLornan, Marie Robin, Nicolaus Kröger

Bone Marrow Transplant 59(8) 1084-1091

PMID38664589
PMCIDPMC11296945
DOI10.1038/s41409-024-02282-7
发表日期2024-04-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

Short-term outcome of myeloablative (MAC) and reduced intensity (RIC) conditioning in the prospective randomized international EBMT RICMAC study in patients with myelodyplastic syndrome (MDS) was comparable but longer follow up is lacking. Patients with MDS aged 18-65 years were randomized to receive MAC (N = 64) with busulfan/cyclophosphamide or RIC (n = 65) with busulfan/fludarabine followed by stem cell transplantation -(HCT) from HLA matched or mismatched donor. After a median follow-up of 6.2 (0.4-12.5) years, 10-year OS and RFS were 54.0% and 43.9% for RIC and 44.4% and 44.2% for MAC (p = 0.15 and p = 0.78), respectively. Since the first report, 6 patients died on NRM, 4 after RIC, and 2 after MAC. Similarly, 8 patients relapsed (4 in each arm), increasing the number of relapsed patients to 28. The second HCT was performed in 18 pts, 8 in the MAC, and 10 in the RIC arm. In a multivariate analysis, ECOG status and chemotherapy prior to HCT were independent risk factors for OS and RFS, ECOG and low cytogenetic risk for NRM and chemotherapy prior to HCT for RI. Patients with low cytogenetic risk had better OS [p = 0.002], RFS [p = 0.02], and NRM (p = 0.015) after RIC as compared to MAC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。